Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$678.4m

Phathom Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Steve Basta

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure4.2yrs

Recent management updates

Recent updates

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 25

Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump

Jun 02
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
author-image

Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity

Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.

Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Apr 18
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Dec 11

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 18

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Aug 02

The Prognosis For Phathom Pharmaceuticals

Jun 22

Phathom Pharmaceuticals: Undiscovered Gem

Jan 20

CEO

Steve Basta (59 yo)

less than a year
Tenure

Mr. Steven L. Basta, also known as Steve, M.B.A., serves as Chief executive Officer, President and Director at Phathom Pharmaceuticals, Inc. from April 1, 2025. He is Director of DermBiont, Inc. He served...

Leadership Team

NamePositionTenureCompensationOwnership
Azmi Nabulsi
Co-Founderno dataUS$2.04m1.33%
$ 9.1m
Steven Basta
CEO, President & Directorless than a yearno datano data
Robert Breedlove
VP of Finance & Principal Accounting Officerless than a yearno datano data
Jonathan Bentley
Senior VP and Head of Salesless than a yearno datano data
Bill Aprea
Senior VP & Chief Compliance Officerless than a yearno datano data
Anne Cook
Chief Legal Officer & Corporate Secretaryno datano datano data
Susan Kim
Senior Vice President of Marketingless than a yearno datano data
Paul Cocja
Chief People Officer1.2yrsno datano data
Eckhard Leifke
Chief Medical Officer5.5yrsno datano data
Jay Buchanan
Senior Vice President of Manufacturing & Supply Chainless than a yearno datano data
Mark Devlin
Senior Vice President of Market Accessless than a yearno datano data
0.08yrs
Average Tenure
63yo
Average Age

Experienced Management: PHAT's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Basta
CEO, President & Directorless than a yearno datano data
Michael Cola
Independent chairman of the Board5.8yrsUS$331.34k0.014%
$ 95.4k
Heidi Fields
Independent Director5.8yrsUS$287.17k0.013%
$ 87.6k
James Topper
Independent Director2.8yrsUS$267.14k0.031%
$ 210.4k
Frank Karbe
Independent Director3.2yrsUS$283.84k0.054%
$ 365.2k
Theodore Schroeder
Directorless than a yearno data0.030%
$ 204.5k
Asit Parikh
Independent Director5.5yrsUS$279.67k0.12%
$ 827.9k
Mark Stenhouse
Independent Director5.3yrsUS$283.84k0.013%
$ 87.6k
4.2yrs
Average Tenure
61yo
Average Age

Experienced Board: PHAT's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 04:26
End of Day Share Price 2025/06/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.
Chase KnickerbockerCraig-Hallum Capital Group LLC